TL;DR
This paper provides the first comprehensive bibliometric map of tetrandrine research, analyzing over 20 years of global scientific output. The study reveals a steady growth in interest, identifying China as the dominant research hub and highlighting a significant strategic shift toward using this plant-derived alkaloid in cancer therapy and overcoming multidrug resistance.
What Problem Does This Paper Address?
Tetrandrine (TET) is a bisbenzylisoquinoline alkaloid originally isolated from the Chinese medicinal plant Stephania tetrandra S. Moore (known as "Fangji"). While it has been a staple of traditional medicine for treating inflammation and hypertension, recent decades have seen a "surging number" of studies exploring its potential in modern pharmacology—particularly oncology.
Despite this influx of research, the field lacked a "compass." Researchers didn't have a quantitative overview of the global landscape: who are the most influential authors? Which institutions are leading the charge? What are the emerging "hotspots" versus fading trends? This paper uses bibliometric analysis to synthesize 22 years of data, providing a roadmap for future drug development and clinical research.
Methods
The authors conducted a retrospective quantitative analysis of literature published between 2000 and 2021. Their workflow involved:
- Data Retrieval: A targeted search of the Web of Science (WOS) Core Collection using specific title-based terms (Tetrandrine, Sinomeninea, or Hanfangchin A).
- Software Stack:
- Microsoft Excel 2019 for basic frequency and percentage calculations.
- VOSviewer (v1.6.17) for generating network visualization maps of co-authorship and keyword clusters.
- RStudio for calculating complex citation metrics (H-index, G-index, and M-index).
- CiteSpace for identifying "citation bursts"—keywords that suddenly spike in popularity, indicating a shift in research focus.
Datasets
The primary dataset consisted of 490 documents retrieved from the WOS Core Collection. After excluding corrections and retractions, 482 documents (predominantly original research articles and meeting abstracts) were included in the final analysis.
Key Insights and Ideas
- The "China Factor": China is the undisputed leader in this field, contributing over 80% of the total publications (362 articles). This is likely due to the plant's indigenous status and its long history in the Chinese Pharmacopoeia.
- The Oncology Pivot: While TET was historically studied for arthritis and inflammation, the keyword analysis shows a massive cluster around "oncology." Specifically, TET is being heavily researched for its ability to reverse multidrug resistance (MDR) in cancer cells by inhibiting P-glycoprotein.
- Collaboration Hubs: The Chinese Academy of Sciences emerged as a critical "collaborating center," showing the highest level of inter-institutional cooperation.
- Influential Voices: While Zhang H. (Jinan University) was the most prolific author by volume, Cheng Y. (National Taiwan University Hospital) was identified as the most influential first author, signaling high-impact leadership in the field.
- Journal Preferences: Acta Pharmacologica Sinica is the "home" of TET research, maintaining the highest H-index and total citations in this niche.
Key Results
- Growth Trends: Publication volume grew from just 9 articles in 2000 to a peak of 42 in 2020.
- Citation Impact: The year 2002 remains the most "impactful" in terms of total citations (820), largely due to seminal work on reversing tumor cell resistance.
- Top Countries: Following China, the United States and South Korea are the next most significant contributors, though their volume is substantially lower.
- Keyword Bursts: The term "proliferation" has shown the strongest citation burst in recent years (2016–2021), indicating a current focus on the molecular pathways TET uses to stop cancer cell growth.
Limitations and Future Work
The authors acknowledge several constraints:
- Database Bias: By only using the Web of Science, the study may have missed relevant papers indexed exclusively in PubMed, Scopus, or Google Scholar.
- Search Specificity: Searching only by "Title" (TI) ensures high accuracy but may have excluded papers where tetrandrine was a secondary focus mentioned only in the abstract.
- Citation Lag: Newer, potentially groundbreaking papers naturally have lower citation counts than older ones, which can skew "influence" metrics toward older research.
Future Directions: The paper concludes that the "frontier" of TET research lies in its application for cancer treatment and arthritis. Specifically, developing better delivery systems (like nanoemulsions) to improve TET's bioavailability remains a promising area for upcoming researchers.
Summary updated